Concepedia

Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression

Zhi Xiong, Tong Tong, Zhaoxiang Xie, Shun-Li Yu, Ruilin Zhuang, Qiang Jia, Shirong Peng, Bingheng Li, Junjia Xie, Kaiwen Li,

Biomaterials Science · 2023 · 11 citations · 25 references

DOI

Concepts

Abstract

, it has been verified that GEF@PLGA NPs exhibit selective accumulation in the tumor and effectively restrain tumor growth. Therefore, the GEF@PLGA NPs hold great promise for the treatment of PCa.

References

25

Cancer statistics, 2023

Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.7K citations · Full text

, , +16

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Vicki L. Keedy, Sarah Temin, Mark R. Somerfield et al. · Journal of Clinical Oncology · 2011 · 486 citations

, , +14

Polydopamine free radical scavengers

Junfei Hu, Lei Yang, Peng Yang et al. · Biomaterials Science · 2020 · 284 citations

, , +17

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Christina M. Canil, Malcolm J. Moore, Eric Winquist et al. · Journal of Clinical Oncology · 2005 · 207 citations

, , +8

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

Luther W. Brady, Curtis Miyamoto, David Woo et al. · International Journal of Radiation Oncology*Biology*Physics · 1992 · 147 citations

, , +16